秋水仙碱(Colchicine) - 药物靶点：Tubulin_在研适应症：动脉粥样硬化，冠心病，家族性地中海热_专利_临床

概要

基本信息

简介武田制药公司于 1995 年 1 月批准秋水仙碱标志着医学界的一个重要里程碑。这种小分子药物属于受人尊敬的微管蛋白聚合抑制剂类，可阻碍细胞中微管的形成。这种治疗机制已被证明对治疗一系列疾病特别有益，包括痛风、家族性地中海热和心包炎。通过阻碍嗜中性粒细胞（在这些情况下是炎症的核心细胞）的运动，秋水仙碱可有效减轻受影响关节和其他组织的疼痛和肿胀。尽管有其优点，但秋水仙碱有一些潜在的副作用，例如胃肠道不适和肌肉无力，这些副作用在较高剂量时可能更为明显。尽管如此，秋水仙碱仍然是治疗各种炎症的重要药物。

药物类型

小分子化药

别名

Colchicine、Colchicine (JP17/USP)、colchicine USP

+ [10]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

免疫系统疾病心血管疾病遗传病与畸形+ [3]

在研适应症

动脉粥样硬化冠心病家族性地中海热+ [5]

非在研适应症

急性心肌梗塞心房颤动高尿酸血症+ [1]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

昆药集团股份有限公司

南方科技大学

AGEPHA PHARMA s.r.o.

+ [8]

非在研机构

Mutual Pharmaceutical Co., Inc.Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceutical Co., Ltd.

+ [2]

权益机构

Scilex Pharmaceuticals, Inc.

Romeg Therapeutics LLC

Avion Pharmaceuticals LLC

最高研发阶段批准上市

首次获批日期

中国 (1995-01-01),

痛风

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C22H25NO6

InChIKeyIAKHMKGGTNLKSZ-INIZCTEOSA-N

CAS号64-86-8

关联

442

项与秋水仙碱相关的临床试验

NCT07232069

/ Not yet recruiting临床3期IIT

Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
1. A Screening Study - Participants will be assessed for plaque by one or both of these scans.
* Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
* Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
* Rosuvastatin 20 mg: a cholesterol-lowering medicine
* Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.

开始日期2026-07-01

申办/合作机构

Duke University

[+4]

NCT06396858

/ Not yet recruiting临床4期IIT

A 2 x 2 Factorial Randomized Clinical Trial Evaluating Anti-inflammatory and Anti-thrombotic Strategy in Acute Ischemic Stroke

The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.

开始日期2026-07-01

申办/合作机构-

NCT07432529

/ Not yet recruiting临床3期IIT

Design and Rationale of the COLT Study: a Multicentre, Randomised, Double-blind, Placebo-controlled Trial of COLchicine as Adjunctive Therapy to Standard Anticoagulation in Acute Proximal Deep Vein Thrombosis of the Lower Limbs

Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep veins of the leg and can lead to long-term problems such as leg pain, swelling, and reduced quality of life. Standard treatment with blood-thinning medication lowers the risk of complications, but some patients still develop long-term damage to the veins. Inflammation is thought to play an important role in these complications.
This study will evaluate whether adding colchicine, an anti-inflammatory medication already used for other conditions, to standard anticoagulant therapy can improve outcomes in patients with acute DVT. Participants will be randomly assigned to receive either colchicine or a placebo, in addition to usual blood-thinning treatment, and will be followed for one year.
The main goal of the study is to determine whether colchicine reduces the risk of developing long-term vein problems after DVT. The study will also assess the risk of new blood clots, vein recovery, quality of life, and the safety of colchicine treatment.

开始日期2026-06-01

申办/合作机构-

100 项与秋水仙碱相关的临床结果

登录后查看更多信息

100 项与秋水仙碱相关的转化医学

登录后查看更多信息

100 项与秋水仙碱相关的专利（医药）

登录后查看更多信息

20,030

项与秋水仙碱相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Evidence-based recommendations for the treatment of recurrent aphthous stomatitis: insights from an umbrella review

Review

作者: AlShehri, Bayan K. ; Alhomood, Khalid S. ; Abuhasna, Waad R. ; Al-Shamiri, Hashem M. ; Al-Maweri, Sadeq Ali ; Al-Aizari, Nader A. ; Alzahrani, Saeed R.

OBJECTIVE:

To compare the effectiveness and safety of pharmacological, physical, and complementary interventions for recurrent aphthous stomatitis (RAS) across clinically relevant outcomes.

METHODS:

This umbrella review was conducted according to PRISMA and Cochrane guidance and registered in PROSPERO (CRD42024594292). PubMed, Scopus, and the Cochrane Library were searched through August 2025. Eligible studies were systematic reviews, meta-analyses, or network meta-analyses evaluating treatments for RAS. Methodological quality was assessed using AMSTAR 2, and overlap of primary studies was quantified using the corrected covered area.

RESULTS:

A total of 41 reviews were included. Topical corticosteroids and low-level laser therapy consistently reduced pain and shortened healing time, although evidence for recurrence prevention was limited. Hyaluronic acid and herbal agents demonstrated favorable short-term efficacy with good safety profiles. Systemic agents such as colchicine and thalidomide showed benefit in severe or refractory RAS, but were constrained by the adverse effects and low-certainty evidence.

CONCLUSION:

Evidence supports topical corticosteroids, hyaluronic acid, and laser therapy for short-term symptom control in RAS, while systemic agents should be reserved for selected refractory cases.

2026-12-01·Molecular & general genetics : MGG

Creation of new varieties of tetraploid willow (Salix suchowensis) and their evaluation for salt tolerance

Article

作者: Chen, Yanhong ; Liu, Guoyuan ; Kan, Siwei ; Li, Mengru ; Wei, Hui ; Mei, Yandong ; Deng, Mingchao ; Qian, Chaonan ; Zhang, Jian

To break the germplasm bottleneck that constrains afforestation in coastal and inland saline alkali soils, this study focused on Salix spp., a fast growing, ecological tree genus, and aimed to establish a highly efficient, low chimera protocol for tetraploid willow induction through refined colchicine treatment. The overarching objective was to expand forest genetic diversity and provide both theoretical insights and elite plant materials for the development of salt-tolerant willow cultivars. The colchicine-based chromosome doubling procedure was systematically optimized; 0.1% (w/v) colchicine for 12 h was identified as the optimal condition, and ploidy levels were verified by flow cytometry. Compared with the diploid controls, the induced tetraploids exhibited pronounced gigas characteristics: leaf length and width increased by 1.6- and 1.4-fold, respectively, and leaf fresh weight was 2.4-fold higher. After 14 d of 50 mmol/L NaCl treatment, tetraploids contained only 50% of the K⁺ level observed in diploids, resulting in a significantly higher K⁺/Na⁺ ratio. POD activity in tetraploids was approximately twice that of diploids, and total chlorophyll content was likewise 1.2-fold higher, collectively demonstrating superior growth performance and physiological homeostasis under saline conditions. These results demonstrate that the optimized chromosome doubling protocol markedly improves tetraploid induction efficiency and effectively enhances the salt tolerance of S. suchowensis. Future research will integrate whole genome re-sequencing to dissect dosage effects and identify key genomic loci governing salt tolerance, establish a marker assisted selection framework for accelerated tetraploid breeding, and conduct multi-site field trials to comprehensively evaluate stability and ecological adaptability. Such efforts are expected to expedite the commercial deployment of high salt tolerant willow cultivars in coastal shelter belt construction and large-scale saline alkali land restoration.

2026-07-01·ANALYTICAL BIOCHEMISTRY

A bioinformatics-guided analytical approach for drug repositioning: Colchicine as a candidate for gaucher disease treatment

Article

作者: Kim, Sung-Jo ; Kim, Jeongin

Gaucher disease is a rare lysosomal storage disorder characterized by lipid accumulation. Emerging evidence suggests that patients with gaucher disease are at an increased risk of developing melanoma, yet the shared molecular mechanisms remain unclear. This study aimed to investigate and validate potential biomarkers commonly expressed in gaucher disease and melanoma through an integrated approach combining bioinformatics, in silico, and in vitro analyses. Gene expression profiles of gaucher disease and melanoma were downloaded from the Gene Expression Omnibus (GEO). Webgestalt was used to identify key pathways and genes. Enriched pathways and genes were detected using the Enrichr platform for commonly expressed genes. Cytoscape software identified 14 hub genes, from which one key gene was selected using a validation dataset from GEO. SwissADME was used to predict 8 drug candidates. Docking analysis was performed to validate the binding capacity of protein and drug candidates. Among them, colchicine exhibited lipid accumulation-inhibiting effects in a gaucher cell model, suggesting it as a potential therapeutic candidate.

1,250

项与秋水仙碱相关的新闻（医药）

2026-04-22

·医药代表

药品暂停进口，两家外企被点名！

又是印度药企，今年以来已有多家被点名。今日（4 月 22 日），国家药监局发布《关于暂停进口、销售和使用Alkaloids Bioactives Private Limited和Alchem International Private Ltd秋水仙碱原料药的公告（2026年第40号）》，暂停了两家外企原料药的进口，并采取对已使用上述原料药生产的制剂不得放行等措施。据《公告》，近期，国家药监局组织对Alkaloids Bioactives Private Limited秋水仙碱原料药（登记号：Y20190009002；生产地址：834 (P), Medchal Shamirpet Road, Medchal Mandal, Medchal-Malkajgiri District, Telangana–501 401, India）和Alchem International Private Ltd秋水仙碱原料药（登记号：Y20190009011、Y20190009012、Y20190009013；生产地址：25/2 Main Mathura Road, Village Kaili, Ballabgarh, Faridabad - 121004, Haryana, India）开展现场检查。经查，上述两家企业在秋水仙碱原料药生产过程中，变更管理存在缺陷，未按照中国药品上市后变更管理法规的要求获得批准或者备案即实施变更，不符合我国《药品生产质量管理规范（2010年修订）》及附录有关要求。根据《中华人民共和国药品管理法》第九十九条、《药品医疗器械境外检查管理规定》第三十条等有关规定，国家药监局决定，自即日起：暂停进口上述原料药，各口岸药品监督管理部门暂停发放该原料药产品的进口通关单。上述原料药在国家药监局药品审评中心“原辅包登记信息”中“与制剂共同审评审批结果”调整为“I”（即未通过与制剂共同审评审批）。上述原料药不得在境内销售、不得用于药品制剂生产，对已使用上述原料药生产的制剂不得放行；已上市放行的制剂，药品上市许可持有人应当立即开展调查与评估，并根据评估结果采取必要的风险控制措施。 ▌ 均为印度药企，Alchem 二度被点名长期关注 MRCLUB 的小伙伴们应该都看到了，今年以来，国家药监局加大对印度 API 供应商的境外检查力度，重点关注变更管理、生产地址一致性、工艺合规等。今日公告涉及的两家公司又均为印度药企，Alkaloids Bioactives Private Limited 是一家来自印度的植物来源原料药企业，生产基地位于印度特伦甘纳邦海得拉巴附近。这家公司隶属于 1967 年成立的 Alkaloids 公司，是印度植物来源 API 生产商之一。据官方介绍，公司主要从事植物提取来源的原料药、营养保健原料和功效型护肤原料生产，产品覆盖秋水仙碱、硫秋水仙苷、利血平、阿马林等，其中秋水仙碱和硫秋水仙苷被列为其重点产品。此次被国家药监局点名的秋水仙碱原料药，对应的正是其位于 Medchal 的生产地址。另一家被点名的 Alchem International Private Ltd 同样来自印度，是一家历史更久的植物化学和天然来源活性成分企业。其官网显示，公司创立于 1935 年，长期从事植物来源活性成分在医药、化妆品和营养保健等领域的开发和生产，秋水仙碱也是其公开展示的重要医药活性成分之一，除药用活性成分外，Alchem 的业务还延伸至化妆品活性物、营养原料以及天然尼古丁等领域，整体上属于印度植物化学原料赛道中较有规模和国际化基础的企业。此次公告涉及的秋水仙碱原料药，对应的是其位于印度哈里亚纳邦法里达巴德的生产地址。秋水仙碱主要用于相关制剂生产，按照公告要求，已使用上述原料药生产制剂的企业需要尽快开展调查评估，并根据评估结果采取必要的风险控制措施，对相关制剂企业而言，原料替代和供应链评估的重要性也随之上升。值得注意的是，Alchem 并非首次因原料药问题被中国监管公开点名。国家药监局 2026 年第 31 号公告显示，2026 年 3 月，Alchem International Private Limited 的利血平、地高辛原料药已被暂停进口、销售和使用（见 MRCLUB 历史消息：三种原料药暂停进口，不得销售）。由此看，此次秋水仙碱原料药被暂停，已是 Alchem 近期第二次因原料药问题被国家药监局公开采取措施。近日热点阅读：盘点！B司中国合作周看点超800亿！印度药王要买下这一跨国药企销售涉贿被开！威高发布致歉声明从副总转岗专员？同仁堂人事变动引关注已更新！2026重点监控药品名单国家医保局：这35种情况可举报不只做仿制药！印度医药产业要换打法？毕井泉被逮捕，已提起公诉！第四批中成药国采正式开始突发！这家跨国药企出清OTC业务拜耳赫新诺®中国获批国药控股原董事长，获刑12年诺华CEO，入局AI大厂国家中医药管理局原局长被逮捕、起诉宗忱就任和铂医药总裁总裁离任，普药裁员，9成MR用AI 又有16家药企进入案源线索名单一周两连发，药物发现大模型竞争打响重磅！速福达®儿童剂型扩龄至1岁+ 6.5亿美元出手！优时比押注这一新疗法一知名药企副总被留置调查 70亿美元豪赌！礼来，盯上了这个新赛道高效能医药代表的7个习惯，你都做到了吗？赛诺菲疫苗全国热招中安斯泰来泌尿团队全国热招拜耳最新全国热招职位一览最新药企内部招聘（4月18日更新） #跨国药企在进博会医药代表伴您成长！

2026-04-22

·药品圈

现场检查发现问题！NMPA暂停进口、销售和使用2家外企的秋水仙碱原料药

近期，国家药监局组织对Alkaloids Bioactives Private Limited秋水仙碱原料药（登记号：Y20190009002；生产地址：834 (P), Medchal Shamirpet Road, Medchal Mandal, Medchal-Malkajgiri District, Telangana–501 401, India）和Alchem International Private Ltd秋水仙碱原料药（登记号：Y20190009011、Y20190009012、Y20190009013；生产地址：25/2 Main Mathura Road, Village Kaili, Ballabgarh, Faridabad - 121004, Haryana, India）开展现场检查。　　经查，上述两家企业在秋水仙碱原料药生产过程中，变更管理存在缺陷，未按照中国药品上市后变更管理法规的要求获得批准或者备案即实施变更，不符合我国《药品生产质量管理规范（2010年修订）》及附录有关要求。　　根据《中华人民共和国药品管理法》第九十九条、《药品医疗器械境外检查管理规定》第三十条等有关规定，国家药监局决定，自即日起：　　一、暂停进口上述原料药，各口岸药品监督管理部门暂停发放该原料药产品的进口通关单。　　二、上述原料药在国家药监局药品审评中心“原辅包登记信息”中“与制剂共同审评审批结果”调整为“I”（即未通过与制剂共同审评审批）。　　三、上述原料药不得在境内销售、不得用于药品制剂生产，对已使用上述原料药生产的制剂不得放行；已上市放行的制剂，药品上市许可持有人应当立即开展调查与评估，并根据评估结果采取必要的风险控制措施。　　特此公告。国家药监局 2026年4月20日

2026-04-22

·医药经济报

国家药监局发布关于暂停进口、销售和使用Alkaloids Bioactives Private Limited和Alchem International Private Ltd秋水仙碱原料药的公告

国家药监局关于暂停进口、销售和使用Alkaloids Bioactives Private Limited和Alchem International Private Ltd秋水仙碱原料药的公告（2026年第40号）近期，国家药监局组织对Alkaloids Bioactives Private Limited秋水仙碱原料药（登记号：Y20190009002；生产地址：834 (P), Medchal Shamirpet Road, Medchal Mandal, Medchal-Malkajgiri District, Telangana–501 401, India）和Alchem International Private Ltd秋水仙碱原料药（登记号：Y20190009011、Y20190009012、Y20190009013；生产地址：25/2 Main Mathura Road, Village Kaili, Ballabgarh, Faridabad - 121004, Haryana, India）开展现场检查。经查，上述两家企业在秋水仙碱原料药生产过程中，变更管理存在缺陷，未按照中国药品上市后变更管理法规的要求获得批准或者备案即实施变更，不符合我国《药品生产质量管理规范（2010年修订）》及附录有关要求。根据《中华人民共和国药品管理法》第九十九条、《药品医疗器械境外检查管理规定》第三十条等有关规定，国家药监局决定，自即日起：一、暂停进口上述原料药，各口岸药品监督管理部门暂停发放该原料药产品的进口通关单。二、上述原料药在国家药监局药品审评中心“原辅包登记信息”中“与制剂共同审评审批结果”调整为“I”（即未通过与制剂共同审评审批）。三、上述原料药不得在境内销售、不得用于药品制剂生产，对已使用上述原料药生产的制剂不得放行；已上市放行的制剂，药品上市许可持有人应当立即开展调查与评估，并根据评估结果采取必要的风险控制措施。特此公告。来源：国家药监局药品GSP零售连锁质量管理附录公开征求意见两部门优化药材进口口岸增设检查标准，促进中药材通关便利化 “十五五”系列主题发布会| 聚焦创新药、医疗卫生强基、全生命周期服务如何落地，国办权威解答→ www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

100 项与秋水仙碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00570	秋水仙碱	M04AC01	DB01394

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
动脉粥样硬化	美国	AGEPHA PHARMA s.r.o.	2023-06-16
冠心病	加拿大	PharmaSciences, Inc.	2021-08-23
家族性地中海热	美国	Takeda Pharmaceuticals U.S.A., Inc.	2009-07-29
痛风	中国	-	1995-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心肌炎	临床3期	法国	Hospices Civils de Lyon	2024-07-16
心房颤动	临床3期	-	ELPEN Pharmaceutical Co., Inc.	2017-12-02
原发性痛风	临床3期	美国	Takeda Pharmaceutical Co., Ltd.	2007-04-01
急性心肌梗塞	临床2期	法国	Hospices Civils de Lyon	2018-07-23
高尿酸血症	临床2期	美国	Takeda Pharmaceutical Co., Ltd.	2014-05-01
心脏衰竭	临床前	中国	重庆医科大学	2025-07-12
血管钙化	临床前	中国	南方科技大学	2025-06-14
心包炎	临床前	美国	ACARPIA Farmaceutici S.r.l.	2024-10-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05850091 (PROACT 2, Pubmed \| J Am Coll Cardiol)	临床4期	冠心病	204	Colchicine + Colchicine	構鹽鹹製餘窪積鬱鹹選(齋壓壓願膚鹹範壓艱膚) = 醖鬱獵觸願餘範糧積壓襯觸餘齋鏇選選窪鹽鹹 (選鬱膚鏇網鏇鑰築觸夢 ) 更多	积极	2026-02-01
ACR2025	N/A	皮肤血管炎	208	Colchicine	-	积极	2025-10-24
				Glucocorticoids	繭顧淵鹹積廠繭鬱蓋簾(鏇醖餘積簾餘壓鹹餘夢) = 鹽觸顧選憲壓鏇鹽選簾膚製獵壓廠廠艱醖鏇網 (願鹹壓築繭鹹簾網願獵 )
Pubmed \| Nat Commun	临床2期	主动脉瓣狭窄	120	Colchicine	襯夢襯簾淵鏇顧窪壓範(膚積窪醖膚衊鑰獵鏇餘): RD = -15.0 (95.0% CI, -28.3 ~ -1.7), P-Value = 0.031 更多	积极	2025-07-15
				Placebo
NCT03310125 (COP-AF, Pubmed \| CJC Open)	临床3期	心房颤动 \| 心肌损伤	3,209	Colchicine 0.5 mg	夢鹹淵網蓋艱構構鹹積(醖醖構網餘憲範鑰窪淵) = 構鹽積獵網網範積蓋鑰積鹽鹹鑰餘鹹獵廠壓糧 (鹽齋鏇繭憲淵窪膚鹹壓 ) 更多	积极	2025-07-01
				Placebo	夢鹹淵網蓋艱構構鹹積(醖醖構網餘憲範鑰窪淵) = 願窪憲獵窪鏇簾鏇壓構積鹽鹹鑰餘鹹獵廠壓糧 (鹽齋鏇繭憲淵窪膚鹹壓 ) 更多
NCT05439356 (CHANCE-3, Pubmed \| EClinicalMedicine)	临床3期	脑卒中 \| 病理性缩窄 intracranial artery stenosis	7,567	Colchicine	積鬱選選顧膚網淵壓鬱(襯憲壓獵構觸艱憲膚願) = 餘範鹽艱淵範壓獵鬱獵淵衊艱窪築鏇範壓蓋構 (艱膚鬱範憲積遞艱夢鏇 ) 更多	不佳	2025-06-01
				Placebo	積鬱選選顧膚網淵壓鬱(襯憲壓獵構觸艱憲膚願) = 觸鏇餘積醖築網憲製齋淵衊艱窪築鏇範壓蓋構 (艱膚鬱範憲積遞艱夢鏇 ) 更多
NCT06342609 (EKSTROM, NEWS) 人工标引	临床4期	冠心病辅助	-	低剂量秋水仙碱（0.5 mg/d）	醖簾鬱鑰製壓夢鹹艱鹹(獵積範顧願糧構衊鬱夢) = 壓顧艱壓鑰積網憲簾襯糧壓選糧網獵製餘膚獵 (淵遞範鬱觸選窪餘鏇淵 ) 未达到更多	积极	2025-04-10
NEWS \| Literature 人工标引	N/A	多发性骨髓瘤	56	秋水仙碱	蓋鬱鹽積憲襯鬱網願衊(願選憲繭範築鹹蓋襯淵) = 範築淵願廠鏇簾簾憲觸獵繭遞鏇範蓋積窪積網 (積夢範觸製蓋膚網糧襯, 77.8–79.1) 更多	积极	2025-03-12
				对照组	蓋鬱鹽積憲襯鬱網願衊(願選憲繭範築鹹蓋襯淵) = 壓窪襯壓觸鏇簾鹹窪膚獵繭遞鏇範蓋積窪積網 (積夢範觸製蓋膚網糧襯, 54.9 ~ 56.1) 更多
NCT03913442 (CLOAK, CTgov)	临床4期	疼痛 \| 炎症 \| 膝关节炎	120	Placebo oral capsule (Placebo)	衊製蓋網糧構餘淵鹹齋(餘選鏇膚鑰獵顧鑰壓衊) = 鑰構顧鏇衊遞鑰構顧膚餘壓築艱壓壓鏇衊積憲 (範繭廠夢觸艱範簾構築, 2.45) 更多	-	2025-02-03
				Colchicine (Colchicine)	衊製蓋網糧構餘淵鹹齋(餘選鏇膚鑰獵顧鑰壓衊) = 遞願願觸壓廠齋膚蓋蓋餘壓築艱壓壓鏇衊積憲 (範繭廠夢觸艱範簾構築, 2.22) 更多
ISC2025	N/A	短暂性脑缺血发作 \| 急性缺血性卒中 high sensitivity C-reactive protein	-	Colchicine	積艱壓築願獵衊餘鑰餘(鹽襯鬱鏇衊鹽積積夢鬱): HR = 0.98 (95% CI, 0.83 ~ 1.16), P-Value = 0.79	-	2025-01-30
				Placebo
NCT06567678 (ECLIPSE Pilot Study, Pubmed \| Cardiol Ther)	临床1期	冠心病	-	Colchicine 0.5 mg	醖顧觸淵顧糧糧夢糧構(壓醖鏇蓋艱衊鏇鹽鏇鑰) = 築簾選範齋鹹鹹製廠餘窪鑰廠膚鹽繭製夢衊齋 (襯夢廠齋築遞構餘襯築 ) 更多	不佳	2025-01-18